ABBV Novinky na Forexe

AbbVie Boosts FY24 Outlook - Update

AbbVie Boosts FY24 Outlook - Update

While reporting financial results for the second quarter on Thursday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2024.
RTTNews | Pred 150 dňami
AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis

AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis

AbbVie, Inc. (ABBV) announced Friday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ 15 mg, once daily) for the treatment of adult patients with giant cell arteritis (GCA).
RTTNews | Pred 163 dňami
AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients

AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients

AbbVie, Inc. (ABBV) announced Tuesday that a new weight-based oral solution RINVOQ LQ (upadacitinib) is now available as an option for pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
RTTNews | Pred 201 dňami
AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin

AbbVie Announces Topline Results From Phase 2 LUMINOSITY Trial Of Telisotuzumab-Vedotin

Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The trial demonstrated compelling clinical benefits across key endpoints.
RTTNews | Pred 389 dňami
AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint

AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint

AbbVie (ABBV) announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.
RTTNews | Pred 450 dňami
AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab

AbbVie Reports Top-line Results From Phase 3 SEQUENCE Clinical Trial Of Risankizumab

Biopharmaceutical company AbbVie, Inc. (ABBV) announced Tuesday top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg subcutaneous injection [SC] starting at week 12 and every 8 weeks thereafter) versus ustekinumab (STELARA, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) through week 48 in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.
RTTNews | Pred 467 dňami
AbbVie Submits Applications For New Indication  To FDA And EMA For Ulcerative Colitis

AbbVie Submits Applications For New Indication To FDA And EMA For Ulcerative Colitis

Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for risankizumab (SKYRIZI, 1200 mg intravenous [IV] [induction dose] as well as 180 mg and 360 mg subcutaneous [SC] [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis.
RTTNews | Pred 482 dňami